Description: Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Home Page: www.pacira.com
5401 West Kennedy Boulevard
Tampa,
FL
33609
United States
Phone:
813 553 6680
Officers
| Name | Title |
|---|---|
| Mr. Daryl Gaugler | Chief Operating Officer |
| Ms. Kristen Williams J.D. | Chief Administrative Officer & Secretary |
| Mr. David M. Stack | Advisor |
| Mr. Charles A. Reinhart III, CPA, M.B.A. | Executive Officer |
| Dr. Jonathan Slonin M.D. | Chief Medical Officer |
| Mr. Frank D. Lee | CEO & Director |
| Mr. Shawn M. Cross | Chief Financial Officer |
| Ms. Lauren Bullaro Riker | Principal Accounting Officer & Senior VP of Finance |
| Ms. Susan Mesco | Head of Investor Relations |
| Mr. Anthony Molloy III, Esq. | Chief Legal & Compliance Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 5.5556 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1737 |
| Price-to-Sales TTM: | 1.1959 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 711 |